ERK Inhibitor JSI-1187 in Advanced Solid Tumors
NCT06239623 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2024-02-02
Summary
JSI-1187-101 phase 1 study
Conditions
Interventions
- DRUG
-
JSI-1187
Use ERK inhibitor JSI-1187 to treat solid tumor
Sponsors & Collaborators
-
JS InnoPharm, LLC
lead INDUSTRY
Principal Investigators
-
Lin Shen, PhD · Beijing Cancer Hosptial
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-04-02
- Primary Completion
- 2024-09-28
- Completion
- 2024-12-30
Countries
- China
Study Locations
More Related Trials
-
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
NCT06050980 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors
NCT05145179 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
NCT07283198 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
NCT05394831 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
NCT05132777 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase I Study of FXS887 in the Treatment of Solid Tumors
NCT07345637 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
NCT05435248 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
NCT03807778 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
NCT06391944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC
NCT05818982 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).
NCT05141786 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Evaluate D-1553 in Subjects With Lung Cancer
NCT05383898 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
NCT02001896 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT05104788 ·Status: RECRUITING ·Phase: PHASE2
-
AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
NCT04993391 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC
NCT05737563 ·Status: RECRUITING ·Phase: PHASE3
-
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
NCT06362980 ·Status: RECRUITING ·Phase: PHASE1
-
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
NCT05503888 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT04239833 ·Status: UNKNOWN ·Phase: PHASE3
-
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
NCT05011487 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
NCT06868732 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
NCT04448379 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer
NCT05186506 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
NCT01458249 ·Status: COMPLETED ·Phase: PHASE2